TGWHomo sapiens (Human)Cancer cell line

Also known as: TGW-nu-1, TGW-I-nu, TGW-nu, TOG

🤖 AI SummaryBased on 6 publications

Quick Overview

Human neuroblastoma cell line with MYCN amplification and genomic alterations.

Detailed Summary

The TGW cell line is a human neuroblastoma-derived cell line established from a 23-month-old Japanese boy with disseminated neuroblastoma. It exhibits MYCN amplification, a common genetic alteration in neuroblastoma, and has been used in studies to investigate the molecular mechanisms of tumor progression and therapeutic targets. TGW has also been involved in research on genomic instability and copy number variations, contributing to understanding the genetic basis of neuroblastoma. The cell line is part of a collection of neuroblastoma models used in cancer research, providing insights into the disease's genetic heterogeneity and potential treatment strategies.

Research Applications

Genomic instability and copy number variationsMYCN amplification in neuroblastomaMolecular mechanisms of tumor progressionTherapeutic target identification

Key Characteristics

MYCN amplificationGenomic alterationsNeuroblastoma model

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1771
Species	Homo sapiens (Human)
Tissue Source	Adrenal gland[UBERON:UBERON_0002369]

Donor Information

Age	1
Age Category	Pediatric
Sex	Male

Disease Information

Disease	Neuroblastoma
Lineage	Peripheral Nervous System
Subtype	Neuroblastoma
OncoTree Code	NBL

DepMap Information

Source Type	JCRB
Source ID	ACH-001674_source

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

8,11

D16S539

9,13

D18S51

D21S11

30,33.2

D3S1358

D5S818

D7S820

D8S1179

FGA

Penta D

9,10

Penta E

11,12

TH01

6,7

TPOX

10,11

vWA

14,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Oncogenic mutations of ALK kinase in neuroblastoma.";

Hayashi Y., Mano H., Ogawa S.

Nature 455:971-974(2008).

DOI PubMed

High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.

Maris J.M.

Genes Chromosomes Cancer 43:390-403(2005).

DOI PubMed

Malignant rhabdoid tumor shows incomplete neural characteristics as revealed by expression of SNARE complex.

Yoshida S., Narita T., Taga T., Ohta S., Takeuchi Y.

J. Neurosci. Res. 69:642-652(2002).

DOI PubMed

Origin of human neuroblastoma cell lines TGW and TNB1.";

Tsuchida Y., Sekiguchi M., Kaneko Y., Kanda N.

FEBS Lett. 263:191-191(1990).

DOI PubMed

Web Resources

thermofisher.com